An oral vaccine for hepatitis b: Challenges, setbacks, and breakthroughs
Biotechnology in Agriculture and Forestry, ISSN: 0934-943X, Vol: 68, Page: 197-228
2014
- 2Citations
- 6Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Despite the commercialization of a highly effective injectable vaccine for over 20 years, the hepatitis B virus (HBV) continues to be a significant health concern worldwide. An estimated 240 million people are chronically infected with the virus despite efforts by the World Health Organization (WHO) to implement child vaccination programs in all WHO member countries for over 10 years. Plants hold the promise of bringing us one step closer to eradication of the disease by providing a low-cost, heat stable, oral alternative to the parenteral vaccine. Several technical hurdles have been overcome over the last several years and a maize-based vaccine has emerged as the front-runner oral vaccine candidate. This review outlines those technical hurdles in the context of hepatitis B epidemiology and socioeconomic factors influencing adoption of vaccination compliance. Additional hurdles to commercialization, such as regulatory considerations and production, are also discussed.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84929517068&origin=inward; http://dx.doi.org/10.1007/978-3-662-43836-7_11; https://link.springer.com/10.1007/978-3-662-43836-7_11; https://dx.doi.org/10.1007/978-3-662-43836-7_11; https://link.springer.com/chapter/10.1007/978-3-662-43836-7_11
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know